GLAND PHARMA LIMITED

Gland Pharma Limited reported strong financial performance for Q1 FY27, with revenues of INR 18,003 million, reflecting a 20% year-on-year growth. The adjusted EBITDA was INR 5,102 million, with a margin of 28%, and profit after tax reached INR 3,170 million, marking a 47% increase year-on-year. Management highlighted growth driven by the CDMO and B2B segments, recent product launches, and improved operational efficiency. The CDMO segment contributed INR 8,915 million, while the B2B segment also contributed INR 9,088 million, both showing healthy growth. The U.S. market remained the largest, with revenues of INR 9,810 million, up 32% year-on-year. Management noted ongoing investments in capacity expansion and strategic collaborations, including a significant agreement for manufacturing sterilized injectables. The company remains focused on maintaining profitability while pursuing growth opportunities across various markets.

Management emphasized strong growth and operational efficiency in the earnings call.